Amantadine Shows Promise as Added Therapy for Hepatitis C
- Amantadine Shows Promise as Added Therapy for Hepatitis C
(The full text pdf file for this will be available online tomorrow
at both Hep C Vets and Hepatitis Central)
Adding amantadine as a third drug to the standard therapy of
interferon alfa-2a and ribavirin may help hepatitis C sufferers who
have never been treated, according to a study reported in the June
issue of Hepatology.
The use of amantadine, a drug used to treat Parkinson's disease, in
patients with chronic hepatitis C is controversial because of its
side effects, including depression, restlessness, irritability and
A team of German researchers compared the triple therapy with the
standard combination therapy of interferon alfa-2a plus ribavirin.
The study involved 400 previously untreated patients with chronic
hepatitis C who received triple therapy with amantadine sulphate or
a placebo for 48 weeks.
Sustained viral response was observed in 52 percent of the
amantadine group and in 43.5 percent of the placebo group. Among
patients with hepatitis C genotype 1 infection, the sustained viral
response rates were 39 percent for those taking amantadine and 31
percent in the placebo group.
The researchers said their findings suggests that amantadine should
be considered as a potential anti-hepatitis C drug in future
SOURCE:Hepatology 2003 Jun;37(6):1359-1367
Do you Yahoo!?
Yahoo! Calendar - Free online calendar with sync to Outlook(TM).